Floatz logo

Daraxonrasib

Malignant Pancreatic Neoplasm

Revolution Medicines, Inc.UNKNOWNPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

314 Active assets in the Malignant Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
Fluorouracilum
Jonsson Comprehensive Cancer Center
Phase 4BBB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Daraxonrasib is also rated in:

pancreatic ductal adenocarcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
pancreatic adenocarcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
pancreatic adenosquamous carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →